The Effect of Dupilumab on Exercise Capacity in Patients with Moderate to Severe Asthma
ClinicalTrials.gov identifier NCT04203797
Brief summary:
The main purpose of this research study is to determine if the investigational drug Dupilumab is effective in improving how long you exercise, and how active you are. Dupilumab is currently not FDA approved for this use.
Dupilumab is a type of drug called a “monoclonal antibody”. An antibody is a special kind of protein that your immune (defense) system normally makes to fight bacteria and viruses. Scientists can now make antibodies in the laboratory and produce them so they can be tested for different diseases.
You may be eligible to participate if you meet all of the following criteria:
- Are 18 to 55 years old
- Use treatment every day for your asthma, but are otherwise healthy
- Are not currently smoking, vaping, or tobacco chewing or cessation of any of these within 6 months
- Are willing to exercise on a stationary bicycle
Note: Other protocol defined inclusion/exclusion criteria apply.
Study participants receive $150 per in-office visit, including the screening visit. Total compensation, if all visits are completed, is $900. Please speak to your coordinator about any needed transportation accommodations.
Promotional Video Promotional Flyer
Please contact us to learn more.
For Clinical Trial Recruitment
Study Sponsor: Regeneron Pharmaceuticals
